Highlights and Quick Summary
- Total Debt for the quarter ending September 29, 2021 was $90.1 Million (a 81.81% increase compared to previous quarter)
- Year-over-year quarterly Total Debt increased by 83.75%
- Annual Total Debt for 2020 was $49 Million (a 107.94% increase from previous year)
- Annual Total Debt for 2019 was $23.6 Million (a 1108.87% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Total Debt of Phathom Pharmaceuticals, Inc.Most recent Total Debtof PHAT including historical data for past 10 years.
Interactive Chart of Total Debt of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Total Debt for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.